



24TH GWANGJU INTERNATIONAL INTERVENTIONAL CARDIOLOGY SYMPOSIUM (GICS) 2026

11-13 June 2026 | Kimdaejung Convention Center, Gwangju, Korea

Introduction

OrbusNeich participated in the 24th Gwangju International Interventional Cardiology Symposium (GICS 2026), held from 11–13 June 2026 at the Kimdaejung Convention Center in Gwangju, Korea.

As one of Korea's premier interventional cardiology meetings, GICS brought together leading cardiologists, cardiovascular specialists, and industry partners from across the Asia-Pacific region to exchange insights on the latest advances in cardiovascular intervention.



Notable Highlights at GICS

- Live case demonstrations covering CTO, AMI, TAVR, and complex PCI procedures.
- Expert-led discussions on intracoronary imaging, physiology-guided intervention, bifurcation treatment, and cardiogenic shock management.
- Focus on emerging technologies, including the integration of artificial intelligence into cardiovascular practice.



Key Achievements

Throughout the congress, OrbusNeich showcased its coronary intervention portfolio with a primary focus on Sapphire® NC 24. The team achieved the following:

- Highlighted the clinical value of Sapphire® NC 24 in complex PCI procedures, including post-stent optimisation and the treatment of calcified lesions.
- Engaged with physicians and key opinion leaders from Chonnam National University Hospital (CNUH) and other leading cardiovascular centres, expanding awareness of the OrbusNeich portfolio.
- Generated strong interest and positive feedback on Sapphire® NC 24, particularly regarding its high-pressure performance and precise sizing.
- Strengthened collaboration with distributor partners and expanded engagement with regional stakeholders.

SAPPHIRE® NC 24
Coronary Dilatation Catheter



GICS 2026 provided an excellent platform for OrbusNeich to reinforce its presence within the Korean interventional cardiology community. Through meaningful interactions with industry partners, the congress positioned NC24 as a clinically differentiated product across multiple procedural discussions and further strengthened OrbusNeich's position in the market.